Market Place
Sourcing Support
Palleon & Henlius Partner to Advance Glycan for Autoimmune Diseases
19 Dec 2024 //
BUSINESSWIRE
Palleon Pharma GLIMMER-01 E-602 + Cemiplimab Data at SITC
08 Nov 2024 //
BUSINESSWIRE
Palleon to Present New Findings on Colorectal Tumor Microenvironment
31 Oct 2023 //
BUSINESSWIRE
Palleon Pharma Recognized as a Fierce Biotech “Fierce 15” Company for 2023
28 Aug 2023 //
BUSINESSWIRE
Palleon Pharma First Patient Dosed with E-602 in Combination with Cemiplimab
22 Jun 2023 //
BUSINESSWIRE
Palleon Presents Initial Phase 1 Results from the GLIMMER-01 Trial for E-602
18 Apr 2023 //
BUSINESSWIRE
Palleon to Present at the Guggenheim Healthcare Talks Oncology Day
07 Feb 2023 //
BUSINESSWIRE
Palleon Announces Issuance of Patent for Use of Antibody Sialidase Conjugates
13 Oct 2022 //
BUSINESSWIRE
Palleon Pharma to Present at the Oppenheimer Healthcare Private Company Showcase
12 Oct 2022 //
BUSINESSWIRE
Palleon to Present on Phase 1/2 E-602 Bi-Sialidase Trial Design at SITC
11 Oct 2022 //
BUSINESSWIRE
Palleon and Henlius Enter into Strategic Collaboration for Sialidase Therapies
28 Jun 2022 //
BUSINESSWIRE
Palleon Presents PC Data on Lead Program E-602 and PD-L1-Targeted Sialidase
08 Apr 2022 //
BUSINESSWIRE
Palleon to Present PC Data on E-602 & Bifunctional PD-L1-Targeted Sialidase
09 Mar 2022 //
BUSINESSWIRE
Palleon Pharma Begins Dosing in Phase 1/2 Study of Glyco-Immunology Drug
08 Mar 2022 //
BUSINESSWIRE
Palleon Pharma Announces IND Clearance for Cancer Immunotherapy
20 Jan 2022 //
BIOSPACE
Palleon Presents Data on Sialoglycan Degradation Platform That Enhances
09 Nov 2021 //
BIOSPACE
Palleon to Present Preclinical Data on Lead Immuno-Oncology Program, E-602
25 Oct 2021 //
BUSINESSWIRE
Palleon Pharmaceuticals Appoints David Feltquate as Chief Medical Officer
09 Jun 2021 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.